Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/11/2021 -- Results Q2 2021 -7.28 -5.98 -21.76%
02/11/2021 11:30 EST Earnings Call Q2 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date --
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 02/11/2021
Beat/Miss Upgrade
Return Since -94.61%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
URL https://www.inmedpharma.com
Investor Relations URL http://www.inmedpharma.com/s/stock-info.asp
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Feb. 11, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-4.17%
47.83%
526.2%
-76.05%
-29.40%
-44.61%
-60.18%
-77.98%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
--
--
--
--
--
--
-89.76%
-42.86%
--
--
--
--
--
-64.74%
147.2%
-97.35%
--
--
--
-90.53%
-28.07%
-63.19%
-1.73%
-76.05%
--
--
--
--
--
--
-81.41%
-39.14%
As of October 04, 2022.

Profile

Edit
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
URL https://www.inmedpharma.com
Investor Relations URL http://www.inmedpharma.com/s/stock-info.asp
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Feb. 11, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter INM Tweets